Cosmo Pharmaceuticals N.V. (ETR:C43)
Germany
· Delayed Price · Currency is EUR 50.00
0.00 (0.00%)
At close: Apr 17, 2025, 5:30 PM CET
Cosmo Pharmaceuticals Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 133.24 | -10.78 | 17.23 | 21.67 | -7.9 | Upgrade
|
| Depreciation & Amortization | 12.29 | 11.85 | 13.86 | 7.37 | 5.06 | Upgrade
|
| Other Amortization | - | - | - | - | 0.97 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | - | -3.97 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.62 | 0.13 | 0 | - | 0.24 | Upgrade
|
| Loss (Gain) From Sale of Investments | -2.35 | -0.95 | -0.09 | 0.68 | 0.25 | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | - | -17.75 | 4.94 | Upgrade
|
| Stock-Based Compensation | 2.07 | 3.83 | 2.08 | 1.46 | 9 | Upgrade
|
| Provision & Write-off of Bad Debts | 2.43 | 1.02 | - | - | - | Upgrade
|
| Other Operating Activities | 14 | 16.66 | 13.47 | 3.89 | 9.45 | Upgrade
|
| Change in Accounts Receivable | 9.24 | 5.19 | -14.16 | 3.29 | -7.92 | Upgrade
|
| Change in Inventory | 0.69 | -2.7 | 1.62 | -6.07 | 0.44 | Upgrade
|
| Change in Accounts Payable | -0.01 | 0.9 | -0.93 | 0.47 | 0.61 | Upgrade
|
| Change in Unearned Revenue | - | 1.4 | 0.51 | -0.94 | - | Upgrade
|
| Change in Income Taxes | -3.2 | -3.55 | -2.74 | -1.36 | -0.05 | Upgrade
|
| Change in Other Net Operating Assets | -6.59 | -0.3 | 2.39 | -0.46 | 1.78 | Upgrade
|
| Operating Cash Flow | 162.41 | 22.71 | 33.23 | 12.61 | 12.99 | Upgrade
|
| Operating Cash Flow Growth | 615.22% | -31.66% | 163.47% | -2.88% | - | Upgrade
|
| Capital Expenditures | -4.55 | -3.35 | -4.52 | -5.49 | -4.12 | Upgrade
|
| Cash Acquisitions | - | - | - | 23.34 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -1.1 | -1.05 | -2.79 | -2.99 | -3.97 | Upgrade
|
| Investment in Securities | -123.45 | 56.78 | -18.13 | 6.74 | 107.48 | Upgrade
|
| Other Investing Activities | 0.23 | 0.83 | 2.13 | 3.06 | 0.82 | Upgrade
|
| Investing Cash Flow | -128.88 | 53.22 | 1.69 | 24.86 | 75.45 | Upgrade
|
| Long-Term Debt Repaid | -1.08 | -176.03 | -0.92 | -2.62 | -1.79 | Upgrade
|
| Net Debt Issued (Repaid) | -1.08 | -176.03 | -0.92 | -2.62 | -1.79 | Upgrade
|
| Issuance of Common Stock | 3.38 | 0.69 | 0.27 | 0.76 | - | Upgrade
|
| Repurchase of Common Stock | -5.93 | -12.48 | -24.75 | -20.51 | -5.72 | Upgrade
|
| Common Dividends Paid | -32.09 | -16.89 | -15.61 | - | - | Upgrade
|
| Other Financing Activities | -4.5 | -6.56 | -5.13 | -4.88 | -4.38 | Upgrade
|
| Financing Cash Flow | -40.22 | -211.27 | -46.13 | -27.25 | -11.88 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.72 | -0.21 | -1.52 | 2.4 | -1 | Upgrade
|
| Net Cash Flow | -5.98 | -135.55 | -12.74 | 12.62 | 75.55 | Upgrade
|
| Free Cash Flow | 157.86 | 19.36 | 28.71 | 7.12 | 8.87 | Upgrade
|
| Free Cash Flow Growth | 715.35% | -32.56% | 303.00% | -19.64% | - | Upgrade
|
| Free Cash Flow Margin | 59.17% | 20.87% | 28.12% | 10.95% | 14.54% | Upgrade
|
| Free Cash Flow Per Share | 9.62 | 1.20 | 1.75 | 0.42 | 0.61 | Upgrade
|
| Cash Interest Paid | - | 4.38 | 4.38 | 4.38 | 4.38 | Upgrade
|
| Cash Income Tax Paid | 7.47 | 3.98 | 1.96 | 2.63 | -2.87 | Upgrade
|
| Levered Free Cash Flow | 117.61 | 19.07 | 11.7 | -10.47 | 1.41 | Upgrade
|
| Unlevered Free Cash Flow | 117.65 | 24.4 | 17.43 | -4.85 | 6.87 | Upgrade
|
| Change in Net Working Capital | -15.89 | -14.29 | 8.73 | 12.14 | 1.21 | Upgrade
|
Updated Jul 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.